Pharma Technology Focus is free for the iPad. Download our app to read the latest issue and browse our back issues for free.
Researchers in Scotland have developed a world-first 3D printing technique which allows them to print human stem cells derived from a donor’s own tissues. We explore the possibilities offered by this breakthrough, which could pave the way for lab-grown human tissues for use in research and, ultimately, replacement organs.
This year’s Nobel Prize in Medicine honoured the developers of a drug that has radically lowered incidences of river blindness and lymphatic filariasis. We take a look back at their research and the impact it has had on global health.
We also get a regulatory outlook for the life sciences sector for the coming year and get a market forecast for Novartis’ newly approved drug Entresto from GlobalData. Plus, we investigate the growing divide between big pharma and healthcare practitioners in the UK, and ask how the relationship between the two sides can be improved for the benefit of patients.
In this issue
Different AgendasA recent industry survey by Binleys indicated that more than 40% of UK GPs view the pharma industry in a negative light. Abi Millar asks Sarah Eglington, healthcare intelligence director at Binley’s, where the schisms lie and what can be done to improve collaboration.Read the article.
Crunch Time: 2016 Regulatory OutlookWith so many regulatory milestones converging next year, ProductLife Group chief operating officer John Farrell examines how companies can meet all of their obligations and get something out of the process.Read the article.
A Breakthrough with Immeasurable ImpactScientists William C. Campbell and Satoshi Omura were honoured with one half of this year’s Nobel Prize in Medicine for discovering a drug that has radically lowered incidences of river blindness and lymphatic filariasis. Elly Earls finds out how their work has contributed to global health.Read the article.
Entresto: Slow Start, Big Potential?Novartis’ Entresto has won EU approval, but will European sales pick up the slack from the slow start the product has seen on the US market? GlobalData’s analyst for cardiovascular and metabolic disorders Elizabeth Hamson reports.Read the article.
Print and Regenerate Researchers have developed a technique to 3D print stem cells from adult donors. Abi Millar finds out how the resulting lab-engineered human tissue could, in the future, be used for drug testing, disease modelling and organ regeneration.Read the article.
A Matter of TrustThe recent fine issued to Pharmacy2U in the UK for selling customer data has drawn attention to the ethical issues involved in online marketing of pharmaceuticals. Chris Lo explores what can be done to protect patient data.Read the article.
Next issue preview
China’s healthcare system is undergoing rapid reform and the pharmaceutical market is set to benefit strongly. While the market is mostly dominated by generics, patent applications are soaring as drugmakers launch their own products and seek new partners. We take a look inside one of the world’s most attractive emerging pharmaceutical markets.
We also find out how GSK is planning to revitalise its product pipeline with a new wave of innovative treatments in areas including HIV, oncology, respiratory medicine and rare diseases, and investigate what the industry is doing to tackle some of the biggest unmet clinical needs, including dementia, antibiotic resistance and depression. Plus, we take a look at Veeva Systems’ end-to-end solution for setting up new clinical trials, and we hear from University of California researchers about the potential applications for a model they have developed to predict a drug’s side effects on different patients.
Digital magazine FAQ
You can read Pharma Technology Focus for free on the iPad. Download our app from the App Store to read the latest issue and browse the back issues in our archive. Sign up for a in the app and never miss a new issue.
You can also continue to read the desktop version for free on our web viewer. (Browser compatibility: The web viewer works in the latest two version of Chrome, Firefox and Safari, as well as in Internet Explorer 9 and 10. Some features may not be compatible with older browser versions.)